124 related articles for article (PubMed ID: 38087734)
1. Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Fernández-Zapata WF; Gandur Quiroga MN; Cardona Maya WD
Eur Urol; 2024 Apr; 85(4):397. PubMed ID: 38087734
[No Abstract] [Full Text] [Related]
2. Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?
Giunta EF; Gasperoni L; De Giorgi U
Future Oncol; 2024 Feb; 20(4):163-166. PubMed ID: 38323376
[No Abstract] [Full Text] [Related]
3. Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?
Williams ISC; Perera S; Murphy DG; Corcoran NM; Bolton DM; Lawrentschuk N
BJU Int; 2022 Nov; 130(5):580-581. PubMed ID: 35879832
[No Abstract] [Full Text] [Related]
4. Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer.
Maughan BL
Clin Adv Hematol Oncol; 2021 Dec; 19(12):764-766. PubMed ID: 34928930
[No Abstract] [Full Text] [Related]
5. Enzalutamide in Biochemically Recurrent Prostate Cancer.
Pollak M
N Engl J Med; 2024 Jan; 390(1):90. PubMed ID: 38169497
[No Abstract] [Full Text] [Related]
6. Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
Shore ND; Tarazi J; Freedland SJ
N Engl J Med; 2024 Jan; 390(1):90-91. PubMed ID: 38169498
[No Abstract] [Full Text] [Related]
7. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G
Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide for castration resistant prostatic cancer: "real-life" matters!
Sciarra A; Fiori C
Minerva Urol Nephrol; 2021 Aug; 73(4):552-553. PubMed ID: 34494417
[No Abstract] [Full Text] [Related]
9. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
10. Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
Grünwald V; Ohlmann CH; Hadaschik B
Eur Urol; 2022 Jun; 81(6):621. PubMed ID: 35193775
[No Abstract] [Full Text] [Related]
11. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
Kohrt SE; Awadallah WN; Phillips RA; Case TC; Jin R; Nanda JS; Yu X; Clark PE; Yi Y; Matusik RJ; Anderson PD; Grabowska MM
Mol Cancer Ther; 2021 Feb; 20(2):398-409. PubMed ID: 33298586
[TBL] [Abstract][Full Text] [Related]
12. Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.
Pang X; Sun X; Gu Y; He X; Gong K; Song S; Zhang J; Xia J; Liu Z; Cui Y
Signal Transduct Target Ther; 2023 Feb; 8(1):60. PubMed ID: 36759595
[No Abstract] [Full Text] [Related]
13. Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
Nierengarten MB
Cancer; 2023 Aug; 129(15):2278. PubMed ID: 37401895
[No Abstract] [Full Text] [Related]
14. Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
Sun R; Wei LJ
J Clin Oncol; 2022 Dec; 40(36):4278-4279. PubMed ID: 35985008
[No Abstract] [Full Text] [Related]
15. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM
Eur Urol; 2020 Sep; 78(3):347-357. PubMed ID: 32527692
[TBL] [Abstract][Full Text] [Related]
16. Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer.
Mori K; Egawa S; Shariat SF
Eur Urol; 2021 Mar; 79(3):430-431. PubMed ID: 33357991
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland SJ; Gleave M; De Giorgi U; Rannikko A; Pieczonka CM; Tutrone RF; Venugopal B; Woo HH; Ramirez-Backhaus M; Supiot S; Lantz A; Ganguli A; Ivanova J; Kral P; Huang SP; Saad F; Shore ND
NEJM Evid; 2023 Dec; 2(12):EVIDoa2300251. PubMed ID: 38320501
[TBL] [Abstract][Full Text] [Related]
19. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Payne H; Robinson A; Rappe B; Hilman S; De Giorgi U; Joniau S; Bordonaro R; Mallick S; Dourthe LM; Flores MM; Gumà J; Baron B; Duran A; Pranzo A; Serikoff A; Mott D; Herdman M; Pavesi M; De Santis M
Int J Cancer; 2022 Mar; 150(5):837-846. PubMed ID: 34648657
[TBL] [Abstract][Full Text] [Related]
20. Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.
Habuchi T
Eur Urol; 2023 Jul; 84(1):141-142. PubMed ID: 36870797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
